首页> 外文期刊>Advances in Animal and Veterinary Sciences >DNA Prime and Protein Boost Immunization with Combined SOD-L7/L12 Antigen Confers Protection to Mice against Brucella Abortus 544 Challenge
【24h】

DNA Prime and Protein Boost Immunization with Combined SOD-L7/L12 Antigen Confers Protection to Mice against Brucella Abortus 544 Challenge

机译:结合了SOD-L7 / L12抗原的DNA初免和蛋白质增强免疫可保护小鼠免受布鲁氏菌544挑战

获取原文
           

摘要

Brucella abortus is an intracellular pathogen that has zoonotic implication. Currently used live attenuated vaccines have several limitations including interference in serodiagnosis of clinical infection and presence of residual virulence in the vaccine strains. There is an urgent need to develop a safe vaccine for control of brucellosis. Here, we describe development of a DNA vaccine construct by combining two immunodominant antigens namely, copper–zinc superoxide dismutase (Cu–Zn SOD) and L7/L12 ribosomal protein. Both the genes were amplified and ligated together to produce the DNA vaccine construct. The combine gene was further expressed in prokaryotic system to produce recombinant fusion protein. A DNA prime–protein boost strategy was followed to immunize mice. Strong immune response dominated by IgG2a subtype shows immune skewing towards Th1 type. Further we have showed that combined antigen conferred significantly higher level of protection against a challenge infection as compare to single antigen immunization. However, the level of protection conferred by combined antigen was lower that the S19 live vaccine. Our report shows the potential of SOD: L7/L12 combined antigen as candidate vaccine eliciting strong immune response against experimental murine brucellosis
机译:流产布鲁氏菌是一种具有人畜共患意义的细胞内病原体。当前使用的减毒活疫苗具有几个局限性,包括干扰临床感染的血清诊断和疫苗株中残留毒力的存在。迫切需要开发一种用于控制布鲁氏菌病的安全疫苗。在这里,我们通过结合两种免疫优势抗原,即铜锌超氧化物歧化酶(Cu-Zn SOD)和L7 / L12核糖体蛋白,描述了DNA疫苗构建体的开发。将两个基因扩增并连接在一起以产生DNA疫苗构建体。该组合基因在原核系统中进一步表达以产生重组融合蛋白。遵循了DNA首要蛋白质增强策略来免疫小鼠。以IgG2a亚型为主的强免疫反应显示出免疫偏向Th1型。进一步地,我们已经表明,与单抗原免疫相比,组合抗原赋予针对攻击性感染的明显更高的保护水平。但是,结合抗原赋予的保护水平低于S19活疫苗。我们的报告显示了SOD的潜力:L7 / L12联合抗原作为候选疫苗引起针对实验性鼠布鲁氏菌病的强烈免疫反应

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号